Daewoong Pharmaceutical Participates in European Gastroenterology Congress... Announces Research Results on Pexuclue for Gastritis Indication

Daewoong Pharmaceutical UEGW 2022 On-site. [Photo by Daewoong Pharmaceutical]

[Asia Economy Reporter Kwanju Lee] Daewoong Pharmaceutical announced on the 13th that it presented clinical data proving the efficacy and safety of 'Pexuclu,' Korea's 34th new drug, in patients with acute or chronic gastritis at the United European Gastroenterology Week (UEGW 2022) held in Vienna, Austria. The European Gastroenterology Week is the largest European conference consisting of more than 50,000 doctors, healthcare professionals, and scientists worldwide.

This presentation was an analysis of the results of a Phase 3 clinical trial evaluating the efficacy and safety of Pexuclu for gastritis indications. Pexuclu demonstrated superiority over placebo in the efficacy evaluation index, 'the effective rate of gastric mucosal erosion on upper gastrointestinal endoscopy,' with both 20 mg once daily and 10 mg twice daily dosing regimens. Safety evaluation results, including adverse drug reactions, showed no statistically significant difference compared to placebo, and no serious adverse drug reactions occurred.

The first author of the study, Professor Kwangha Kim of the Department of Gastroenterology at Pusan National University Hospital, said, "Just as PPIs (proton pump inhibitors) replaced the existing acid secretion inhibitors, H2 blockers, in the 1990s, P-CABs (potassium-competitive acid blockers) will soon replace PPIs." He added, "Pexuclu, a P-CAB developed recently by Daewoong Pharmaceutical, will play a leading role in this trend."

In addition to the domestic approval for indications such as ▲erosive gastroesophageal reflux disease treatment and ▲improvement of gastric mucosal lesions in acute and chronic gastritis, Daewoong Pharmaceutical is accelerating research to expand Pexuclu's indications. Notably, Phase 3 clinical trials are underway for prevention of NSAIDs-induced gastroduodenal ulcers and maintenance therapy in patients cured of erosive gastroesophageal reflux disease, and clinical trials for Helicobacter eradication therapy are also being prepared.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "Presenting the results of Pexuclu's gastritis indication research at the largest European conference, the European Gastroenterology Week, provided an opportunity to showcase Pexuclu's excellence to medical professionals worldwide." He added, "Daewoong Pharmaceutical plans not only to conduct various domestic and international clinical trials to add follow-up indications for Pexuclu but also to strengthen product competitiveness by expanding the lineup for improved dosing convenience."

This content was produced with the assistance of AI translation services.